Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06650592 · ClinicalTrials.gov registry record

Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA

A clinical trial of Lymphatic Reconstruction, sponsored by University of Chicago.

Recruiting
Registry status
90
Enrollment target
1
Study location

NCT06650592: Recruiting study of Lymphatic Reconstruction, sponsored by University of Chicago.

NCT06650592 is a study of Lymphatic Reconstruction that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06650592, a study of Lymphatic Reconstruction, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
90 participants
Enrollment target
1
Study location

Study Summary

Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema. It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of one or more lymphatic channel with a local recipient vein to re-direct upper extremity lymphatic drainage. Although ILR carries significant promise in prevention of lymphedema, there is a lack of high-level evidence supporting its efficacy because it is a novel surgical technique that is only offered at a few centers and not routinely covered by insurance carriers yet. The University of Chicago Comprehensive Cancer Center (UCCCC) is one of the busiest microsurgery centers performing this procedure, and, as a Lymphedema Center of Excellence, is in a unique position to investigate the efficacy of ILR in preventing lymphedema. In addition, the University has access to a world class microbiome research facility and colleagues. There is no information on the skin microbiome of the axilla in patients undergoing treatment for breast cancer or those at risk for developing lymphedema. Further exploratory studies such as this in a diverse patient population may lead to practice changing research in our approach to lymphedema management and prevention. The purpose of this study is to determine the role of immediate lymphatic reconstruction and obtain objective data to correlate the existing, self-reported rates of lymphedema at the University of Chicago.

Conditions Studied

Interventions

  • OTHER All patients who were candidates for immediate lymphatic reconstruction (ILR)

Study Locations (1)

Illinois

  • The University o Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-11-26
Est. Completion 2029-10
University of Chicago

796 total trials

What NCT06650592 shows while recruiting

NCT06650592 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.

The record links to 1 condition, with Lymphatic Reconstruction appearing as the primary indexed condition, and to 1 intervention - of which All patients who were candidates for immediate lymphatic reconstruction (ILR) is the first listed.

NCT06650592 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06650592 about?

NCT06650592 is a clinical study titled "Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA". Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema. It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of o...

What is the current status of trial NCT06650592?

This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2024-11-26. Estimated completion is 2029-10.

What conditions does trial NCT06650592 study?

This clinical trial studies the following conditions: Lymphatic Reconstruction.

What interventions are being tested in trial NCT06650592?

The interventions under investigation include: All patients who were candidates for immediate lymphatic reconstruction (ILR) (OTHER).

Who is sponsoring clinical trial NCT06650592?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06650592 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphatic Reconstruction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06650592, the US trial registry maintained by the National Library of Medicine. NCT06650592 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.